中文 | English
Return
Total: 26 , 1/3
Show Home Prev Next End page: GO
Author:(Rongguang SHAO)

1.G3BP: a promising target for cancer therapy.

Hao ZHANG ; Rongguang SHAO

Acta Pharmaceutica Sinica 2010;45(8):945-51

2.Sphingosine kinase 1 and tumor.

Caixia ZHANG ; Hongwei HE ; Rongguang SHAO

Acta Pharmaceutica Sinica 2013;48(7):971-8

3.Phosphoprotein EBP50 suppresses proliferation of breast cancer by inhibiting activity of ERK1/2 in MCF-7 cell line

Hong LIU ; Yan MA ; Rongguang SHAO

Chinese Pharmacological Bulletin 2015;(1):55-59

4.Potential targets for anti-liver fibrosis.

Shuangshuang ZHAO ; Rongguang SHAO ; Hongwei HE

Acta Pharmaceutica Sinica 2014;49(10):1365-71

5.Therapeutics, genomics and epigenomics of retinoblastoma

Wenping SONG ; Rongguang SHAO ; Liang LI

Chinese Journal of Biochemical Pharmaceutics 2016;36(6):1-5

6.Advances in antibody drug for cancer targeted therapy

Rui CAO ; Rongguang SHAO ; Liang LI

Chinese Journal of Biochemical Pharmaceutics 2016;36(6):15-18

7.Antitumor Activity of the Conjugates Composed of C1027, an Anticancer Antibiotic, and Monoclonal Antibody

Yongsu ZHEN ; Rongguang SHAO ; Min JIANG

Chinese Journal of Cancer Biotherapy 1995;0(02):-

8.Studies of cancer therapeutic pharmacology in China:Data from 2001 applications of NSFC

Yao DAI ; Lei WU ; Rongguang SHAO

Chinese Pharmacological Bulletin 1986;0(05):-

9.An overview of antibody-based cancer therapy.

Qingfang MIAO ; Rongguang SHAO ; Yongsu ZHEN

Acta Pharmaceutica Sinica 2012;47(10):1261-8

10.The synergistic effect of lidamycin and rituximab on human B cell lymphoma.

Yiran SUN ; Shenghua ZHANG ; Rongguang SHAO ; Hongwei HE

Acta Pharmaceutica Sinica 2014;49(2):198-203

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 26 , 1/3 Show Home Prev Next End page: GO